SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 396 filers reported holding SAREPTA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.80 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $71,802,606 | +5.7% | 592,333 | -0.2% | 0.06% | +7.8% |
| Q2 2023 | $67,950,900 | -48.3% | 593,354 | -37.8% | 0.05% | -51.0% |
| Q1 2023 | $131,379,832 | +48.5% | 953,204 | +39.6% | 0.10% | +44.4% |
| Q4 2022 | $88,459,342 | -17.2% | 682,662 | -29.4% | 0.07% | -23.4% |
| Q3 2022 | $106,859,000 | +20.4% | 966,697 | -18.4% | 0.09% | +28.8% |
| Q2 2022 | $88,786,000 | +38.8% | 1,184,449 | +44.6% | 0.07% | +65.9% |
| Q1 2022 | $63,986,000 | +15430.6% | 819,073 | +33760.0% | 0.04% | – |
| Q4 2020 | $412,000 | +21.9% | 2,419 | +0.5% | 0.00% | – |
| Q3 2020 | $338,000 | -11.7% | 2,407 | +0.8% | 0.00% | – |
| Q2 2020 | $383,000 | -99.4% | 2,387 | -99.4% | 0.00% | -100.0% |
| Q2 2019 | $61,923,000 | +37.3% | 407,524 | +7.7% | 0.06% | +34.8% |
| Q1 2019 | $45,102,000 | -2.9% | 378,407 | -11.1% | 0.05% | -13.2% |
| Q4 2018 | $46,444,000 | -29.3% | 425,580 | +4.6% | 0.05% | -17.2% |
| Q3 2018 | $65,705,000 | +1307.6% | 406,820 | +545.7% | 0.06% | +1180.0% |
| Q1 2018 | $4,668,000 | +47.0% | 63,009 | +10.4% | 0.01% | +66.7% |
| Q4 2017 | $3,175,000 | -3.3% | 57,058 | -21.2% | 0.00% | 0.0% |
| Q3 2017 | $3,284,000 | +76.2% | 72,394 | +30.9% | 0.00% | +50.0% |
| Q2 2017 | $1,864,000 | +68.2% | 55,294 | +47.8% | 0.00% | +100.0% |
| Q1 2017 | $1,108,000 | +7.3% | 37,417 | -0.6% | 0.00% | 0.0% |
| Q4 2016 | $1,033,000 | -55.3% | 37,652 | +0.1% | 0.00% | -66.7% |
| Q3 2016 | $2,309,000 | +254.7% | 37,598 | +10.1% | 0.00% | +200.0% |
| Q2 2016 | $651,000 | -43.7% | 34,156 | +13.9% | 0.00% | 0.0% |
| Q4 2015 | $1,157,000 | -28.4% | 29,987 | -40.4% | 0.00% | -50.0% |
| Q3 2015 | $1,615,000 | +66.8% | 50,308 | +58.1% | 0.00% | +100.0% |
| Q2 2015 | $968,000 | +107.3% | 31,823 | -9.6% | 0.00% | 0.0% |
| Q1 2015 | $467,000 | -8.6% | 35,187 | -0.4% | 0.00% | 0.0% |
| Q4 2014 | $511,000 | -27.4% | 35,339 | +5.9% | 0.00% | 0.0% |
| Q3 2014 | $704,000 | -28.7% | 33,373 | +0.6% | 0.00% | 0.0% |
| Q2 2014 | $988,000 | -25.3% | 33,182 | +18.5% | 0.00% | -50.0% |
| Q3 2013 | $1,323,000 | +32.0% | 28,010 | +6.6% | 0.00% | +100.0% |
| Q2 2013 | $1,002,000 | – | 26,280 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 399,400 | $35,962,000 | 5.36% |
| Avoro Capital Advisors LLC | 3,125,000 | $281,406,000 | 4.79% |
| Varenne Capital Partners | 324,661 | $29,236,000 | 4.34% |
| Evolutionary Tree Capital Management, LLC | 96,695 | $8,707,000 | 4.18% |
| Ally Bridge Group (NY) LLC | 120,000 | $10,806,000 | 3.78% |
| Casdin Capital, LLC | 1,350,000 | $121,568,000 | 3.43% |
| Ghost Tree Capital, LLC | 100,000 | $9,005,000 | 3.23% |
| GREAT POINT PARTNERS LLC | 145,405 | $13,094,000 | 2.91% |
| Camber Capital Management LP | 825,000 | $74,291,000 | 2.55% |
| Alpha DNA Investment Management LLC | 17,522 | $1,577,000 | 1.00% |